ClinicalTrials.gg
CompletedNCT02408549VALUEUpdated Dec 14, 2023Results posted

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

A Phase 3 interventional study of Lacosamide Tablet and Lacosamide Oral Solution in Epilepsy, sponsored by UCB BIOSCIENCES, Inc.. Completed at 87 sites in 21 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.

Primary conditionEpilepsy, Idiopathic GeneralizedRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsy, Idiopathic Generalized
Why
  1. The study's title name Epilepsy, Idiopathic Generalized, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Epilepsy, Idiopathic Generalized with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Epilepsy, Idiopathic Generalized · United States.

Enrollment
3rd of 14
239 · median 61
Started
2015
with 1 other
Phase 3
4 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
4 of 17
UCB BIOSCIENCES, Inc.

Among the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 7th registered.

Epilepsy, Idiopathic Generalized

35 studies on the registry are indexed under Epilepsy, Idiopathic Generalized; 4 are open to participants now.

Browse Epilepsy, Idiopathic Generalized studies →

Open to participants now

2 of the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Epilepsy, Idiopathic Generalized studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Epilepsy, Idiopathic Generalized with a site in United States, or all of them as a file.
02

Study summary

Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects >= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 [NCT02408523] study.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Lacosamide
  • Vimpat
  • Epilepsy
  • Children
  • Primary Generalized Tonic Clonic seizures
  • Idiopathic Generalized Epilepsy
  • Adults
04

In context

Epilepsy, Idiopathic Generalized Reclassified

35 studies on the registry are indexed under Epilepsy, Idiopathic Generalized; 4 are open to participants now.

This study's enrollment of 239 is above the median of 71 across 26 interventional studies indexed under Epilepsy, Idiopathic Generalized.

Browse Epilepsy, Idiopathic Generalized studies →

Lead sponsor

UCB BIOSCIENCES, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Compared within Epilepsy, Idiopathic Generalized, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have completed or be an eligible Baseline failure from the parent study (SP0982 [NCT02408523]). Note: Other subjects screened for SP0982 may be considered for roll-over to EP0012 if the investigator considers that the subject could benefit from treatment with open-label lacosamide (LCM) and based on prior discussion with and approval from the UCB Study Physician or representative

Exclusion criteria

Exclusion Criteria:

  • Subject is receiving any drugs or using any experimental devices in addition to lacosamide (LCM)
  • Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious adverse event (SAE)
  • Subject has an active suicidal ideation as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Since Last Visit" version of the Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Subject has >=2x (ULN) of any of the following: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%). For all subjects who entered EP0012 directly with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any elevation must be understood and recorded in the electronic Case Report form (eCRF). Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Lacosamide

    Start dose SP0982 completers at V1: * LCM 10 mg/kg/day for pediatric subjects weighing \<30 kg * LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to \<50 kg * LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg SP0982 Baseline failures at V1: * LCM 2 mg/kg/day for pediatric subjects weighing \<50 kg * LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg Oral solution (pediatric subjects \<50 kg): * Minimum LCM dose: 4 mg/kg/day * Maximum LCM dose: 12 mg/kg/day Tablets (pediatric subjects ≥50kg): * Minimum LCM dose: 200 mg/day * Minimum LCM dose: 600 mg/day Tablets (adult subjects): * Minimum LCM dose: 200 mg/day * Maximum LCM dose: 800 mg/day

    Drug: Lacosamide Tablet · Drug: Lacosamide Oral Solution

Interventions

  • DrugLacosamideStudies of LacosamideLacosamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * Active substance: Lacosamide * Pharmaceutical form: Tablet * Concentration: 50 mg and 100 mg * Route of Administration: Oral administration

    Also known as: Vimpat, LCM

  • DrugLacosamideStudies of LacosamideLacosamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * Active substance: Lacosamide * Pharmaceutical form: Oral solution * Concentration: 10 mg/ml * Route of Administration: Oral administration

    Also known as: Vimpat, LCM

07

What researchers measure

Primary outcomes

  1. Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period

    AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)

  2. Number of Study Participants Withdrawn Due to TEAEs

    AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)

  3. Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period

    The number of study participants with appearance of new absence and/or myoclonic seizure types experienced during the Treatment Period but who did not experience in Combined Baseline Period or in seizure classification history, before taking LCM were reported. To determine appearance of new seizure type, the Combined Baseline Period was used. Thus, the participants who directly enrolled into EP0012, the Baseline absence, and/or myoclonic seizure data from SP0982's 4-week Prospective Baseline Period were combined with any reported Baseline absence, and myoclonic seizure information in the daily seizure diary from EP0012 (reported before first dose in EP0012) to recalculate the study participant's Baseline variables such as days with absence, and/or myoclonic seizures per 28 days.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)

  4. Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of up to 25% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  5. Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of \>25% to 50% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  6. Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of \>50% to 75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  7. Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of \>75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  8. Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of up to 25% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  9. Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of \>25% to 50% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  10. Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of \>50% to 75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  11. Number of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

    The number of participants experiencing an increase of \>75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period

  12. Percentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures

    Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with absence seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of absence seizures in Prospective Baseline or the Treatment Period.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)

  13. Percentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures

    Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with myoclonic seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of myoclonic seizures in Prospective Baseline or the Treatment Period.

    Time frame: From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)

Secondary outcomes

  1. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin)

    TEMA values are defined in the Statistical Analysis Plan (SAP) as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematology parameter, Hemoglobin were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years (y) to \<17 years', the abnormality criteria were '\<=95' grams/deciliter (g/dL) (Low) and '\>160' g/dL (High). For age range, '\>=17 years', the abnormality Criteria were '\<=85% of lower limit of normal (LLN)' value (Low) and '\>=115% of upper limit of normal (ULN)' value (High) of Hemoglobin in blood.

    Time frame: During the study (up to approximately 5 years)

  2. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hematocrit)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematocrit were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '2 years to \<17 years', the abnormality criteria were '\<=29%' (Low) and '\>47%' (High) hematocrit values. For age range, '\>=17 years', the abnormality criteria were '\<=85% of LLN' (Low) and '\>=115% of ULN' (High) of Hematocrit values in blood.

    Time frame: During the study (up to approximately 5 years)

  3. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Platelets)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Platelet count were those that were observed post-BL during the Treatment Period but not present at BL. For the age range of '\>1 month', the abnormality criteria were '\<=100' 10\^9/L and '\>=600' 10\^9/L of Platelets count value.

    Time frame: During the study (up to approximately 5 years)

  4. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Erythrocytes)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Erythrocytes parameter were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>=2years', the abnormality criteria were '\<3.5' 10\^12/L of Erythrocytes value in blood. Early Termination Visit (TV) was last visit in the study (up to approximately 5 years).

    Time frame: During the study (up to approximately 5 years)

  5. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Leukocytes)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Leukocytes were those that were observed post-BL during the Treatment Period but not present at BL. For all age ranges, the abnormality criteria were '\<=3.0' 10\^9/L (Low) and '\>= 16.0' 10\^9/L (High) of Leukocytes values in blood.

    Time frame: During the study (up to approximately 5 years)

  6. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Basophils Absolute)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Basophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=0.4' 10\^9/L of Basophils in blood.

    Time frame: During the study (up to approximately 5 years)

  7. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Eosinophils Absolute)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Eosinophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=1.0' 10\^9/L of Eosinophils in the blood.

    Time frame: During the study (up to approximately 5 years)

  8. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Lymphocytes Absolute)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Lymphocytes Absolute were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years - \<6 years', the abnormality criteria were '\<0.7' 10\^9/L (Low) and '\>6.9' 10\^9/L (High). For age range, '\>=6 years', the abnormality criteria were '\<0.6' 10\^9/L (Low) and '\>5.0' 10\^9/L (High) for Lymphocytes Absolute in the blood.

    Time frame: During the study (up to approximately 5 years)

  9. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Monocytes Absolute )

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Monocytes Absolute were those that are observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\>=2.0' 10\^9/L of Monocytes in blood.

    Time frame: During the study (up to approximately 5 years)

  10. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Neutrophils Absolute)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Neutrophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\<1.5' 10\^9/L of Neutrophils in blood.

    Time frame: During the study (up to approximately 5 years)

  11. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Calcium)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Calcium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year -\<17 years', the abnormality criteria were '\<=1.85' millimoles per litre (mmol/L) and '\>=2.95' mmol/L. For age range, '\>=17 years', the abnormality criteria was '\<=1.9 mmol/L' and '\>=2.75 mmol/L' of serum Calcium.

    Time frame: During the study (up to approximately 5 years)

  12. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Sodium)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Sodium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<127' mmol/L (Low) and '\>151' mmol/L (High) of serum Sodium.

    Time frame: During the study (up to approximately 5 years)

  13. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Potassium)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Potassium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year', the abnormality criteria were '\<= 3.0' mmol/L (Low) and '\>= 6.0' mmol/L (High) of serum Potassium.

    Time frame: During the study (up to approximately 5 years)

  14. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Chloride)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Chloride were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<=90' mmol/L (Low) and '\>=112' mmol/L (High) of serum Chloride.

    Time frame: During the study (up to approximately 5 years)

  15. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Bicarbonate)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Bicarbonate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were '\<15' mmol/L (Low) and '\>38' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<18' mmol/L (Low) and '\>38' mmol/L (High) of serum Bicarbonate.

    Time frame: During the study (up to approximately 5 years)

  16. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Creatinine)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Creatinine were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1-\<10 years', the abnormality criteria were '\>106.8' micromole per litre (umol/L), for '10-\<16 years', the abnormality criteria were '\>159.12' umol/L and for '\>=16 years', the abnormality criteria was '\>=176.8' umol/L for serum Creatinine.

    Time frame: During the study (up to approximately 5 years)

  17. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Aspartate Aminotransferase)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Aspartate Aminotransferase (AST) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 units per litre (U/L) x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum AST.

    Time frame: During the study (up to approximately 5 years)

  18. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alanine Aminotransferase)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alanine Aminotransferase (ALT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 U/L x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum ALT.

    Time frame: During the study (up to approximately 5 years)

  19. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Chemistry Parameters (Total Bilirubin)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Bilirubin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria was '≥34.208' umol/L of serum Bilirubin.

    Time frame: During the study (up to approximately 5 years)

  20. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alkaline Phosphatase)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alkaline Phosphatase were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '4 years -\<10 years', the abnormality criteria was '\>=834 U/L', for '10 years -\<17 years', the abnormality criteria was '\>=1761 U/L' and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' of serum alkaline phosphatase.

    Time frame: During the study (up to approximately 5 years)

  21. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Gamma Glutamyl Transferase)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Gamma Glutamyl Transferase (GGT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<13 years', the abnormality criteria was '\>=66' U/L (High A), for '13 years-\<17 years', the abnormality criteria was '\>=126' U/L (High B) and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' (High C) of serum GGT.

    Time frame: During the study (up to approximately 5 years)

  22. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Glucose)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Glucose were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were from '\<2.775' mmol/L (Low) and '\>=9.99' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<2.775' mmol/L (Low) and '\>=11.1' mmol/L (High) of serum Glucose.

    Time frame: During the study (up to approximately 5 years)

  23. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Albumin)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Albumin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year to \<17 years', the abnormality criteria were '\<24' g/L and '\>84' g/L and for age range, '\>=17 years', the abnormality criteria was '\<26' g/L of serum albumin.

    Time frame: During the study (up to approximately 5 years)

  24. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Total Protein)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Protein were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year to \<17 years', the abnormality criteria were '\<43' g/L and '\>120' g/L. For age range, '\>=17 years', the abnormality criteria were '\<43' g/L and '\>130' g/L of serum protein.

    Time frame: During the study (up to approximately 5 years)

  25. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Phosphate)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Phosphate were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<17 years', the abnormality criteria were from '\<0.5814' mmol/L (Low) and '\>2.3902' mmol/L (High). For age range, '\>=17 years', the abnormality Criteria were '\<=0.646' mmol/L (Low) and '\>=1.938' mmol/L (High) of serum phosphate.

    Time frame: During the study (up to approximately 5 years)

  26. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead Electrocardiogram (ECG) Parameter (QT Interval)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QT interval parameter were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month (m)-\<12 years', the abnormality criteria were '\>=500 milliseconds (ms)' (Abnormal (Abn) A). For age range, '\>=12 years', the abnormality criteria were '\>=500 ms' (Abn B) or '\>=60 ms increase from Baseline' (Abn C). The abnormality in QT interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.

    Time frame: During the study (up to approximately 5 years)

  27. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(F) Interval)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(F) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were from '\>440 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality Criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(F) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.

    Time frame: During the study (up to approximately 5 years)

  28. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(B) Interval)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(B) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were '\>450 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(B) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.

    Time frame: During the study (up to approximately 5 years)

  29. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (PR Interval)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of PR interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>180 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>200 ms' (Abn C) and '\>25% increase from Baseline' value (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>200 ms' (Abn E), '\>220 ms' (Abn F), or '\>250 ms' (Abn G).

    Time frame: During the study (up to approximately 5 years)

  30. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QRS Interval)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QRS interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>100 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>110 ms' (Abn C) and '\>25% increase from Baseline' (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>100 ms' (Abn E), '\>120 ms' (Abn F), or '\>140 ms' (Abn G).

    Time frame: During the study (up to approximately 5 years)

  31. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (Heart Rate Interval)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of Heart rate interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 beats per minute (bpm)' (Abn A) and '\>130 bpm' (Abn B). For the age range, '\>=12 years', the abnormality criteria were '\<50 bpm' (Abn C) and '\>120 bpm' (Abn D).

    Time frame: During the study (up to approximately 5 years)

  32. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Pulse Rate)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs results of Pulse rate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 bpm' (Low) and '\>130 bpm' (High). For the age range, '12 years - \<17 years', the abnormality criteria were '\<=50 bpm' (Low) and '\>=120 bpm' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=50 bpm and a decrease from Baseline of \>=15 bpm' (Low A), '\>=120 bpm and an increase from Baseline of \>=15 bpm' (High A), '\<60 bpm' (Low B) and '\>100 bpm' (High B). The Pulse rate was reported as per positions such as 'Supine 3 minute (Sup 3 min)', 'Standing 1 minute' (Std 1 min), and 'Standing 3 minute' (Std 3 min).

    Time frame: During the study (up to approximately 5 years)

  33. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Systolic Blood Pressure)

    TEMA values of Systolic Blood Pressure (BP) results were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<80 millimeters of mercury (mmHg)' (Low) and '\>140 mmHg' (High). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\<90 mmHg' (Low) and '\>160 mmHg' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=90 mmHg and decrease from Baseline of \>=20 mmHg' (Low A), '\>=180 mmHg and increase from Baseline of \>=20' mmHg (High A), '\<90 mmHg' (Low B), '\>140 mmHg (High B), and '\>160 mmHg' (High C). Systolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.

    Time frame: During the study (up to approximately 5 years)

  34. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Diastolic Blood Pressure)

    TEMA values of Diastolic BP results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<50 mmHg' (Low) and '\>80 mmHg' (High), '\>=12 years - \<17 years', the abnormality criteria were '\<=50 mmHg' (Low) and '\>=105 mmHg' (High), and '\>=17 years', the abnormality criteria were '\<=50 mmHg and decrease from Baseline of \>=15 mmHg' (Low A), '\>=105 mmHg and increase from Baseline of \>=15' mmHg (High A), '\<50 mmHg' (Low B), '\>90 mmHg' (High B), and '\>100 mmHg' (High C). Diastolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.

    Time frame: During the study (up to approximately 5 years)

  35. Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Body Weight)

    TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs parameter results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month - \<17 years', the abnormality criteria were '\<3% of normal body weight' in Kilograms (kg) or '\>97% of normal body weight' in kgs. Here, '\<3% of normal' is presented as 'Low' and '\>97% of normal' is presented as 'High'. For the age range '\>=17 years', the abnormality criteria were 'Increase/decrease of \>=10%' body weight in kgs (presented as Inc/Dec A) or 'Increase/decrease of \>=7%' body weight in kgs (presented as Inc/Dec B).

    Time frame: During the study (up to approximately 5 years)

  36. Percent Change in Primary Generalized Tonic-clonic Seizure (PGTCS) Frequency Per 28 Days From Combined Baseline

    The 28-day PGTCS frequency during the relative period was subtracted from the 28-day Combined Baseline PGTCS frequency and the result was divided by 28-day Combined Baseline PGTCS frequency and the result was then multiplied by 100 to get percent change in PGTCS frequency per 28 days from Combined Baseline Period (CB) to the appropriate analysis Period. The CB was defined as the combined 12-week Historical Baseline and 4-week Prospective Baseline periods immediately prior to randomization in the study SP0982 or prior to Visit 1 (first dose) if direct enrollers in EP0012.

    Time frame: From Combined Baseline until end of Treatment Period (up to approximately 5 years)

08

Results

Posted Dec 14, 2023

Participant flow

The study started to enroll participants in August 2015 and concluded in March 2023. Study participants from SP0982 \[NCT02408523\], who met EP0012 eligibility criteria were enrolled.

Participant flow — Overall Study
MilestoneAll Participants (Lacosamide)
Started239
Completed157
Not completed82
Withdrew: Adverse event15
Withdrew: Death4
Withdrew: Lack of efficacy17
Withdrew: Protocol violation4
Withdrew: Lost to follow-up6
Withdrew: Consent withdrawn30
Withdrew: Neurology research program closing at site1
Withdrew: Site closure1
Withdrew: Pregnancy1
Withdrew: Withdrawal of consent due to business trip1
Withdrew: Subject moved to another place, far from site1
Withdrew: Study terminated at site1

Outcome measures

PrimaryNumber of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period

AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period222
PrimaryNumber of Study Participants Withdrawn Due to TEAEs

AEs were considered treatment-emergent if event had onset on or after date of first study medication dose in EP0012 and within 30 days following last study medication dose or events whose intensity worsened on or after date of first study medication dose and within 30 days following date of last study medication administration. Adverse Events were reported spontaneously by the participant and/or caregiver or observed by the investigator.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Study Participants Withdrawn Due to TEAEs
ParticipantsAll Participants (Lacosamide)
Number of Study Participants Withdrawn Due to TEAEs19
PrimaryNumber of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period

The number of study participants with appearance of new absence and/or myoclonic seizure types experienced during the Treatment Period but who did not experience in Combined Baseline Period or in seizure classification history, before taking LCM were reported. To determine appearance of new seizure type, the Combined Baseline Period was used. Thus, the participants who directly enrolled into EP0012, the Baseline absence, and/or myoclonic seizure data from SP0982's 4-week Prospective Baseline Period were combined with any reported Baseline absence, and myoclonic seizure information in the daily seizure diary from EP0012 (reported before first dose in EP0012) to recalculate the study participant's Baseline variables such as days with absence, and/or myoclonic seizures per 28 days.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Reported as:
Count of participants · Participants
Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period
ParticipantsAll Participants (Lacosamide)
Absence seizures3
Myoclonic seizures5
PrimaryNumber of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of up to 25% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)5
PrimaryNumber of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of \>25% to 50% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)1
PrimaryNumber of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of \>50% to 75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of >50% to 75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)0
PrimaryNumber of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of \>75% in the number of days with absence seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with absence seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of >75% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)0
PrimaryNumber of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of up to 25% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of up to 25% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)4
PrimaryNumber of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of \>25% to 50% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of >25% to 50% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)1
PrimaryNumber of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of \>50% to 75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of >50% to 75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)1
PrimaryNumber of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)

The number of participants experiencing an increase of \>75% in the number of days with myoclonic seizures per 28 days during the Treatment Period compared to the Prospective Baseline Period (for those participants with myoclonic seizure data reported in the 4-week Prospective Baseline Period in SP0982) were reported. This period started on the day of Visit 1 of SP0982 and ended the day before Visit 2 of SP0982. For the direct enrollers into EP0012, Prospective Baseline ended the day before Visit 1 (or prior to first dose) of EP0012.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years), compared to the Prospective SP0982 Baseline Period
Reported as:
Count of participants · Participants
Number of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)
ParticipantsAll Participants (Lacosamide)
Number of Study Participants With an Increase of >75% in Days With Myoclonic Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982)2
PrimaryPercentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures

Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with absence seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of absence seizures in Prospective Baseline or the Treatment Period.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With at Least 50% Worsening in Days With Absence Seizures0
PrimaryPercentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures

Seizure worsening was defined as a participant experiencing \>=50% increase in the number of days with myoclonic seizures per 28 days from Prospective Baseline. Percentages for seizure worsening were based on those participants who have reported a history of or an occurrence of myoclonic seizures in Prospective Baseline or the Treatment Period.

Time frame:
From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With at Least 50% Worsening in Days With Myoclonic Seizures3.2
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin)

TEMA values are defined in the Statistical Analysis Plan (SAP) as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematology parameter, Hemoglobin were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years (y) to \<17 years', the abnormality criteria were '\<=95' grams/deciliter (g/dL) (Low) and '\>160' g/dL (High). For age range, '\>=17 years', the abnormality Criteria were '\<=85% of lower limit of normal (LLN)' value (Low) and '\>=115% of upper limit of normal (ULN)' value (High) of Hemoglobin in blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hemoglobin)
percentage of participantsAll Participants (Lacosamide)
Low: Week (Wk) 78 (2-<17 y)14.3
Low: Wk 0 (>=17 y)3.7
Low: Wk 2 (>=17 y)0.5
Low: Wk 118 (>=17 y)0.8
Low: Wk 166 (>=17 y)1.2
Low: Wk 214 (>=17 y)2.5
Low: Termination Visit (TV) (>=17 y)1.6
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hematocrit)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Hematocrit were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '2 years to \<17 years', the abnormality criteria were '\<=29%' (Low) and '\>47%' (High) hematocrit values. For age range, '\>=17 years', the abnormality criteria were '\<=85% of LLN' (Low) and '\>=115% of ULN' (High) of Hematocrit values in blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Hematocrit)
percentage of participantsAll Participants (Lacosamide)
High: Wk 22 (2-<17 y)6.9
High: Wk 46 (2-<17 y)3.7
Low: Wk 46 (>=17 y)1.2
Low: Wk 118 (>=17 y)1.6
Low: Wk 166 (>=17 y)1.2
Low: TV (>=17 y)0.8
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Platelets)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Platelet count were those that were observed post-BL during the Treatment Period but not present at BL. For the age range of '\>1 month', the abnormality criteria were '\<=100' 10\^9/L and '\>=600' 10\^9/L of Platelets count value.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Platelets)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Platelets)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Erythrocytes)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Erythrocytes parameter were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>=2years', the abnormality criteria were '\<3.5' 10\^12/L of Erythrocytes value in blood. Early Termination Visit (TV) was last visit in the study (up to approximately 5 years).

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Erythrocytes)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Erythrocytes)1.7
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Leukocytes)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Leukocytes were those that were observed post-BL during the Treatment Period but not present at BL. For all age ranges, the abnormality criteria were '\<=3.0' 10\^9/L (Low) and '\>= 16.0' 10\^9/L (High) of Leukocytes values in blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Leukocytes)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Leukocytes)0.5
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Basophils Absolute)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Basophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=0.4' 10\^9/L of Basophils in blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Basophils Absolute)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Basophils Absolute)0.4
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Eosinophils Absolute)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Eosinophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria were '\>=1.0' 10\^9/L of Eosinophils in the blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Eosinophils Absolute)
percentage of participantsAll Participants (Lacosamide)
>=1.0: Wk 2 (>1 month)0.9
>=1.0: Wk 22 (>1 month)0.5
>=1.0: TV (>1 month)1.5
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Lymphocytes Absolute)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Lymphocytes Absolute were those that were observed post-Baseline (BL) during the Treatment Period but not present at Baseline. For the age range, '2 years - \<6 years', the abnormality criteria were '\<0.7' 10\^9/L (Low) and '\>6.9' 10\^9/L (High). For age range, '\>=6 years', the abnormality criteria were '\<0.6' 10\^9/L (Low) and '\>5.0' 10\^9/L (High) for Lymphocytes Absolute in the blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Lymphocytes Absolute)
percentage of participantsAll Participants (Lacosamide)
High: Wk 2 (>=6 y)0.4
High: Wk 78 (>=6 y)3.2
High: Wk 118 (>=6 y)0.7
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Monocytes Absolute )

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Monocytes Absolute were those that are observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\>=2.0' 10\^9/L of Monocytes in blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Monocytes Absolute )
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Monocytes Absolute )0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Neutrophils Absolute)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Neutrophils Absolute were those that were observed post-BL during the Treatment Period but not present at BL. For the age range, '\>1 month', the abnormality criteria was '\<1.5' 10\^9/L of Neutrophils in blood.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Hematology Parameters (Neutrophils Absolute)
percentage of participantsAll Participants (Lacosamide)
<1.5: Wk 2 (>1 m)0.9
<1.5: Wk 22 (>1 m)0.5
<1.5: Wk 46 (>1 m)0.5
<1.5: Wk 62 (>1 m)0.5
<1.5: Wk 94 (>1 m)0.6
<1.5: Wk 214 (>1 m)2.4
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Calcium)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Calcium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year -\<17 years', the abnormality criteria were '\<=1.85' millimoles per litre (mmol/L) and '\>=2.95' mmol/L. For age range, '\>=17 years', the abnormality criteria was '\<=1.9 mmol/L' and '\>=2.75 mmol/L' of serum Calcium.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Calcium)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Calcium)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Sodium)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Sodium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<127' mmol/L (Low) and '\>151' mmol/L (High) of serum Sodium.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Sodium)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Sodium)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Potassium)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Potassium were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year', the abnormality criteria were '\<= 3.0' mmol/L (Low) and '\>= 6.0' mmol/L (High) of serum Potassium.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Potassium)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Potassium)0.4
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Chloride)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Chloride were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria were '\<=90' mmol/L (Low) and '\>=112' mmol/L (High) of serum Chloride.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Chloride)
percentage of participantsAll Participants (Lacosamide)
High: Wk 2 (>1 m)1.3
High: Wk 22 (>1 m)2.3
High: Wk 46 (>1 m)2.5
High: Wk 62 (>1 m)1.5
High: Wk 78 (>1 m)3.1
High: Wk 94 (>1 m)1.2
High: Wk 118 (>1 m)3.4
High: Wk 214 (>1 m)2.3
High: TV (>1 m)1.4
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Bicarbonate)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Bicarbonate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were '\<15' mmol/L (Low) and '\>38' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<18' mmol/L (Low) and '\>38' mmol/L (High) of serum Bicarbonate.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Bicarbonate)
percentage of participantsAll Participants (Lacosamide)
Low: Wk 2 (>=17 y)1.1
Low: Wk 46 (>=17 y)1.2
Low: Wk 62 (>=17 y)1.3
Low: Wk 94 (>=17 y)0.7
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Creatinine)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Creatinine were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1-\<10 years', the abnormality criteria were '\>106.8' micromole per litre (umol/L), for '10-\<16 years', the abnormality criteria were '\>159.12' umol/L and for '\>=16 years', the abnormality criteria was '\>=176.8' umol/L for serum Creatinine.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Creatinine)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Creatinine)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Aspartate Aminotransferase)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Aspartate Aminotransferase (AST) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 units per litre (U/L) x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum AST.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Aspartate Aminotransferase)
percentage of participantsAll Participants (Lacosamide)
High A: All ages (Early TV)1.7
High A: All ages (TV)0.7
High B: All ages (TV)0.7
High C: All ages (TV)0.7
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alanine Aminotransferase)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alanine Aminotransferase (ALT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For all ages, the abnormality criteria were specified as '≥3.0 U/L x ULN' (High A), '≥5.0 U/L x ULN' (High B), and '≥10.0 U/L x ULN' (High C) of serum ALT.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alanine Aminotransferase)
percentage of participantsAll Participants (Lacosamide)
High A: All ages (Wk 2)0.4
High A: All ages (Wk 46)0.5
High A: All ages (Wk 62)0.5
High A: All ages (Wk 118)0.7
High A: All ages (TV)0.7
High B: All ages (Wk 2)0.4
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Chemistry Parameters (Total Bilirubin)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Bilirubin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month', the abnormality criteria was '≥34.208' umol/L of serum Bilirubin.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Chemistry Parameters (Total Bilirubin)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Chemistry Parameters (Total Bilirubin)0.5
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alkaline Phosphatase)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Alkaline Phosphatase were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '4 years -\<10 years', the abnormality criteria was '\>=834 U/L', for '10 years -\<17 years', the abnormality criteria was '\>=1761 U/L' and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' of serum alkaline phosphatase.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alkaline Phosphatase)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Alkaline Phosphatase)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Gamma Glutamyl Transferase)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Gamma Glutamyl Transferase (GGT) were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<13 years', the abnormality criteria was '\>=66' U/L (High A), for '13 years-\<17 years', the abnormality criteria was '\>=126' U/L (High B) and for '\>=17 years', the abnormality criteria was '\>=3.0 U/L x ULN' (High C) of serum GGT.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Gamma Glutamyl Transferase)
percentage of participantsAll Participants (Lacosamide)
High A: TV (1-<13 y)16.7
High C: Wk 2 (>=17 y)1.0
High C: Wk 22 (>=17 y)0.5
High C: Wk 62 (>=17 y)1.8
High C: Wk 78 (>=17 y)3.4
High C: Wk 118 (>=17 y)0.8
High C: Wk 166 (>=17 y)1.1
High C:TV (>=17 y)0.8
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Glucose)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Glucose were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>1 month-\<17 years', the abnormality criteria were from '\<2.775' mmol/L (Low) and '\>=9.99' mmol/L (High). For age range, '\>=17 years', the abnormality criteria were '\<2.775' mmol/L (Low) and '\>=11.1' mmol/L (High) of serum Glucose.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Glucose)
percentage of participantsAll Participants (Lacosamide)
Low: Wk 2 (>=17 y)0.5
Low: Wk 62 (>=17 y)0.6
Low: Wk 94 (>=17 y)0.7
Low: Wk 118 (>=17 y)0.8
High: Wk 2 (>=17 y)1.0
High: Wk 22 (>=17 y)1.1
High: Wk 46 (>=17 y)1.2
High: Wk 62 (>=17 y)1.8
High: Wk 78 (>=17 y)3.4
High: Wk 94 (>=17 y)0.7
High: Wk 118 (>=17 y)0.8
High: Early TV (>=17 y)1.9
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Albumin)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Albumin were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '\>=1 year to \<17 years', the abnormality criteria were '\<24' g/L and '\>84' g/L and for age range, '\>=17 years', the abnormality criteria was '\<26' g/L of serum albumin.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Albumin)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Albumin)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Total Protein)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Total Protein were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year to \<17 years', the abnormality criteria were '\<43' g/L and '\>120' g/L. For age range, '\>=17 years', the abnormality criteria were '\<43' g/L and '\>130' g/L of serum protein.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Total Protein)
percentage of participantsAll Participants (Lacosamide)
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Total Protein)0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Phosphate)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA laboratory results of Phosphate were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 year-\<17 years', the abnormality criteria were from '\<0.5814' mmol/L (Low) and '\>2.3902' mmol/L (High). For age range, '\>=17 years', the abnormality Criteria were '\<=0.646' mmol/L (Low) and '\>=1.938' mmol/L (High) of serum phosphate.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Serum Chemistry Parameters (Phosphate)
percentage of participantsAll Participants (Lacosamide)
Low: Wk 94 (>=17 y)0.7
Low: Wk 118 (>=17 y)0.8
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead Electrocardiogram (ECG) Parameter (QT Interval)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QT interval parameter were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month (m)-\<12 years', the abnormality criteria were '\>=500 milliseconds (ms)' (Abnormal (Abn) A). For age range, '\>=12 years', the abnormality criteria were '\>=500 ms' (Abn B) or '\>=60 ms increase from Baseline' (Abn C). The abnormality in QT interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead Electrocardiogram (ECG) Parameter (QT Interval)
percentage of participantsAll Participants (Lacosamide)
Abn C: Wk 0 (>=12 years)33.3
Abn C: Wk 2 (>=12 years)0.5
Abn C: Wk 14 (>=12 years)3.3
Abn C: Wk 30 (>=12 years)0.8
Abn B: Wk 46 (>=12 years)0.5
Abn C: Wk 46 (>=12 years)2.7
Abn C: Wk 62 (>=12 years)2.2
Abn C: Wk 78 (>=12 years)1.6
Abn C: Wk 94 (>=12 years)2.5
Abn C: Wk 118 (>=12 years)13.0
Abn C: Wk 142 (>=12 years)6.9
Abn C: Wk 190 (>=12 years)3.2
Abn C: Early TV (>=12 years)3.8
Abn C: TV (>=12 years)2.3
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(F) Interval)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(F) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were from '\>440 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality Criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(F) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(F) Interval)
percentage of participantsAll Participants (Lacosamide)
Abn C: Wk 0 (>=17 y)33.3
Abn D: Wk 0 (>=17 y)33.3
Abn F: Wk 0 (>=17 y)33.3
Abn C: Wk 2 (>=17 y)1.5
Abn F: Wk 2 (>=17 y)1.0
Abn A: Wk 14 (>=12 y-<17 y)5.6
Abn C: Wk 14 (>=17 y)2.1
Abn D: Wk 14 (>=17 y)1.0
Abn E: Wk 14 (>=17 y)0.5
Abn F: Wk 14 (>=17 y)3.7
Abn F: Wk 30 (>=17 y)1.7
Abn C: Wk 46 (>=17 y)5.2
Abn D: Wk 46 (>=17 y)1.7
Abn E: Wk 46 (>=17 y)1.2
Abn F: Wk 46 (>=17 y)2.3
Abn A: Wk 62 (>=12 y-<17 y)6.3
Abn B: Wk 62 (>=12 y-<17 y)6.3
Abn C: Wk 62 (>=17 y)2.4
Abn D: Wk 62 (>=17 y)0.6
Abn F: Wk 62 (>=17 y)1.8
Abn F: Wk 78 (>=17 y)1.8
Abn C: Wk 94 (>=17 y)2.7
Abn D: Wk 94 (>=17 y)2.0
Abn E: Wk 94 (>=17 y)2.0
Abn F: Wk 94 (>=17 y)3.4
Abn C: Wk 118 (>=17 y)9.5
Abn F: Wk 118 (>=17 y)4.8
Abn C: Wk 142 (>=17 y)2.1
Abn F: Wk 142 (>=17 y)2.1
Abn C: Early TV (>=17 y)6.1
Abn D: Early TV (>=17 y)2.0
Abn E: Early TV (>=17 y)2.0
Abn F: Early TV (>=17 y)4.1
Abn C: TV (>=17 y)2.8
Abn F: TV (>=17 y)5.6
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(B) Interval)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QTc(B) interval were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range '3 years -\<12 years' and '\>=12 years- \<17 years', the abnormality criteria were '\>450 ms' (Abn A) and '\>15% increase from Baseline' value (Abn B). For age range, '\>=17 years', the abnormality criteria were '\>450 ms' (Abn C), '\>480 ms' (Abn D), '\>500 ms' (Abn E) or '\>=60 ms increase from Baseline' value (Abn F). The abnormality in QTc(B) interval was observed at Week 0 as the participant was rolled over from SP0982 study and was constantly having abnormal ECG parameters while in SP0982 and EP0012.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QTc(B) Interval)
percentage of participantsAll Participants (Lacosamide)
Abn C: Wk 0 (>=17 y)33.3
Abn D: Wk 0 (>=17 y)33.3
Abn E: Wk 0 (>=17 y)33.3
Abn F: Wk 0 (>=17 y)33.3
Abn C: Wk 2 (>=17 y)3.6
Abn F: Wk 2 (>=17 y)2.0
Abn A: Wk 14 (>=12 y-<17 y)5.6
Abn C: Wk 14 (>=17 y)5.8
Abn D: Wk 14 (>=17 y)1.6
Abn E: Wk 14 (>=17 y)1.0
Abn F: Wk 14 (>=17 y)3.7
Abn C: Wk 30 (>=17 y)2.5
Abn F: Wk 30 (>=17 y)1.7
Abn C: Wk 46 (>=17 y)7.0
Abn D: Wk 46 (>=17 y)2.9
Abn E: Wk 46 (>=17 y)1.2
Abn F: Wk 46 (>=17 y)3.5
Abn A: Wk 62 (>=12 y-<17 y)6.3
Abn B: Wk 62 (>=12 y-<17 y)6.3
Abn C: Wk 62 (>=17 y)2.4
Abn D: Wk 62 (>=17 y)0.6
Abn E: Wk 62 (>=17 y)0.6
Abn F: Wk 62 (>=17 y)3.5
Abn C: Wk 78 (>=17 y)5.4
Abn F: Wk 78 (>=17 y)1.8
Abn C: Wk 94 (>=17 y)5.4
Abn D: Wk 94 (>=17 y)2.0
Abn E: Wk 94 (>=17 y)2.0
Abn F: Wk 94 (>=17 y)3.4
Abn A: Wk 118 (>=12 y-<17 y)50.0
Abn C: Wk 118 (>=17 y)14.3
Abn D: Wk 118 (>=17 y)4.8
Abn E: Wk 118 (>=17 y)4.8
Abn F: Wk 118 (>=17 y)9.5
Abn A: Wk 142 (>=12 y-<17 y)9.1
Abn C: Wk 142 (>=17 y)8.5
Abn F: Wk 142 (>=17 y)4.3
Abn F: Wk 166 (>=17 y)33.3
Abn C: Wk 190 (>=17 y)7.7
Abn F: Wk 190 (>=17 y)3.8
Abn C: Early TV (>=17 y)6.1
Abn D: Early TV (>=17 y)2.0
Abn E: Early TV (>=17 y)2.0
Abn F: Early TV (>=17 y)6.1
Abn C: TV (>=17 y)2.8
Abn D: TV (>=17 y)2.8
Abn F: TV (>=17 y)5.6
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (PR Interval)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of PR interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>180 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>200 ms' (Abn C) and '\>25% increase from Baseline' value (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>200 ms' (Abn E), '\>220 ms' (Abn F), or '\>250 ms' (Abn G).

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (PR Interval)
percentage of participantsAll Participants (Lacosamide)
Abn B: Wk 2 (3 y-<12 y)6.3
Abn D: Wk 2 (>=12 y-<17 y)5.0
Abn E: Wk 2 (>=17 y)1.5
Abn F: Wk 2 (>=17 y)0.5
Abn E: Wk 14 (>=17 y)1.0
Abn E: Wk 30 (>=17 y)1.7
Abn F: Wk 30 (>=17 y)0.9
Abn C: Wk 46 (>=12 y-<17 y)6.3
Abn E: Wk 46 (>=17 y)1.2
Abn B: Wk 62 (3 y-<12 y)20.0
Abn C: Wk 62 (>=12 y-<17 y)6.3
Abn E: Wk 62 (>=17 y)2.9
Abn F: Wk 62 (>=17 y)0.6
Abn E: Wk 78 (>=17 y)5.4
Abn F: Wk 78 (>=17 y)1.8
Abn G: Wk 78 (>=17 y)1.8
Abn B: Wk 94 (3 y-<12 y)28.6
Abn C: Wk 94 (>=12 y-<17 y)7.1
Abn E: Wk 94 (>=17 y)2.7
Abn F: Wk 94 (>=17 y)0.7
Abn G: Wk 94 (>=17 y)0.7
Abn D: Wk 118 (>=12 y-<17 y)50.0
Abn E: Wk 142 (>=17 y)8.7
Abn F: Wk 142 (>=17 y)2.2
Abn E: Early TV (>=17 y)2.0
Abn F: Early TV (>=17 y)2.0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QRS Interval)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of QRS interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\>100 ms' (Abn A) and '\>25% increase from Baseline' value (Abn B). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\>110 ms' (Abn C) and '\>25% increase from Baseline' (Abn D). For age range, '\>=17 years', the abnormality criteria were treatment-emergent values above '\>100 ms' (Abn E), '\>120 ms' (Abn F), or '\>140 ms' (Abn G).

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (QRS Interval)
percentage of participantsAll Participants (Lacosamide)
Abn E: Wk 2 (>=17 y)5.1
Abn D: Wk 14 (>=12 y-<17 y)5.6
Abn E: Wk 14 (>=17 y)9.9
Abn F: Wk 14 (>=17 y)0.5
Abn E: Wk 30 (>=17 y)7.6
Abn A: Wk 46 (3 y-<12 y)8.3
Abn D: Wk 46 (>=12 y-<17 y)6.3
Abn E: Wk 46 (>=17 y)7.6
Abn D: Wk 62 (>=12 y-<17 y)6.3
Abn E: Wk 62 (>=17 y)10.6
Abn F: Wk 62 (>=17 y)1.8
Abn E: Wk 78 (>=17 y)8.9
Abn F: Wk 78 (>=17 y)1.8
Abn C: Wk 94 (>=12 y-<17 y)7.1
Abn D: Wk 94 (>=12 y-<17 y)7.1
Abn E: Wk 94 (>=17 y)6.1
Abn F: Wk 94 (>=17 y)0.7
Abn E: Wk 118 (>=17 y)14.3
Abn E: Wk 142 (>=17 y)10.6
Abn E: Early TV (>=17 y)10.2
Abn E: TV (>=17 y)5.6
Abn F: TV (>=17 y)5.6
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (Heart Rate Interval)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA ECG results of Heart rate interval were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 beats per minute (bpm)' (Abn A) and '\>130 bpm' (Abn B). For the age range, '\>=12 years', the abnormality criteria were '\<50 bpm' (Abn C) and '\>120 bpm' (Abn D).

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in 12-lead ECG Parameter (Heart Rate Interval)
percentage of participantsAll Participants (Lacosamide)
Abn C: Wk 2 (>=12 y)1.4
Abn C: Wk 14 (>=12 y)2.4
Abn C: Wk 30 (>=12 y)1.5
Abn C: Wk 46 (>=12 y)0.5
Abn D: Wk 46 (>=12 y)0.5
Abn C: Wk 62 (>=12 y)3.2
Abn D: Wk 62 (>=12 y)0.5
Abn C: Wk 78 (>=12 y)3.3
Abn C: Wk 94 (>=12 y)1.2
Abn C: Wk 118 (>=12 y)4.3
Abn D: Wk 214 (>=12 y)100
Abn D: TV (>=12 y)2.3
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Pulse Rate)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs results of Pulse rate were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<60 bpm' (Low) and '\>130 bpm' (High). For the age range, '12 years - \<17 years', the abnormality criteria were '\<=50 bpm' (Low) and '\>=120 bpm' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=50 bpm and a decrease from Baseline of \>=15 bpm' (Low A), '\>=120 bpm and an increase from Baseline of \>=15 bpm' (High A), '\<60 bpm' (Low B) and '\>100 bpm' (High B). The Pulse rate was reported as per positions such as 'Supine 3 minute (Sup 3 min)', 'Standing 1 minute' (Std 1 min), and 'Standing 3 minute' (Std 3 min).

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Pulse Rate)
percentage of participantsAll Participants (Lacosamide)
Low B: Wk 2 (>=17 y)-Sup 3 min4.5
High B: Wk 2 (>=17 y)- Sup 3 min0.5
High: Wk 2 (>=12 y-<17 y)-Std 1 min5.0
Low B: Wk 2 (>=17 y)-Std 1 min2.5
High B: Wk 2 (>=17 y)-Std 1 min3.0
Low B: Wk 2 (>=17 y)-Std 3 min1.5
High B: Wk 2 (>=17 y)-Std 3 min2.6
Low A: Wk 6 (>=17 y)-Sup 3 min0.5
Low B: Wk 6 (>=17 y)-Sup 3 min4.6
High B: Wk 6 (>=17 y)-Sup 3 min2.0
High: Wk 6 (>=12 y-<17 y)- Std 1 min4.8
Low B: Wk 6 (>=17 y)- Std 1 min1.5
High B: Wk 6 (>=17 y)- Std 1 min3.1
Low A: Wk 6 (>=17 y)- Std 3 min0.5
Low B: Wk 6 (>=17 y)- Std 3 min1.0
High B: Wk 6 (>=17 y)- Std 3 min2.6
Low B: Wk 14 (>=17 y)- Sup 3 min4.1
High B: Wk 14 (>=17 y)- Sup 3 min1.0
High: Wk 14 (>=12 y-<17 y)- Std 1 min5.6
Low B: Wk 14 (>=17 y)- Std 1 min3.1
High B: Wk 14 (>=17 y)- Std 1 min2.6
Low B: Wk 14 (>=17 y)- Std 3 min0.5
High B: Wk 14 (>=17 y)- Std 3 min4.1
Low B: Wk 22 (>=17 y)- Sup 3 min3.2
High B: Wk 22 (>=17 y)- Sup 3 min0.5
High A: Wk 22 (>=17 y)- Std 1 min0.5
Low B: Wk 22 (>=17 y)- Std 1 min1.6
High B: Wk 22 (>=17 y)- Std 1 min4.2
Low B: Wk 22 (>=17 y)- Std 3 min2.1
High B: Wk 22 (>=17 y)- Std 3 min3.7
Low B: Wk 30 (>=17 y)- Sup 3 min1.7
Low B: Wk 30 (>=17 y)- Std 1 min5.0
High B: Wk 30 (>=17 y)- Std 1 min3.4
Low B: Wk 30 (>=17 y)- Std 3 min2.5
High B: Wk 30 (>=17 y)- Std 3 min1.7
Low B: Wk 38 (>=17 y)- Sup 3 min3.7
Low B: Wk 38 (>=17 y)- Std 1 min2.8
High B: Wk 38 (>=17 y)- Std 1 min5.6
Low B: Wk 38 (>=17 y)- Std 3 min0.9
High B: Wk 38 (>=17 y)- Std 3 min2.8
Low B: Wk 46 (>=17 y)- Sup 3 min5.7
High B: Wk 46 (>=17 y)- Sup 3 min1.7
Low A: Wk 46 (>=17 y)- Std 1 min0.6
High A: Wk 46 (>=17 y)- Std 1 min1.1
Low B: Wk 46 (>=17 y)- Std 1 min4.0
High B: Wk 46 (>=17 y)- Std 1 min5.2
Low B: Wk 46 (>=17 y)- Std 3 min2.9
High B: Wk 46 (>=17 y)- Std 3 min4.6
Low B: Wk 62 (>=17 y)- Sup 3 min5.2
High B: Wk 62 (>=17 y)- Sup 3 min2.3
Low: Wk 62 (>=12 y-<17 y)- Std 1 min6.3
High A: Wk 62 (>=17 y)- Std 1 min0.6
Low B: Wk 62 (>=17 y)- Std 1 min4.6
High B: Wk 62 (>=17 y)- Std 1 min4.0
High A: Wk 62 (>=17 y)- Std 3 min0.6
Low B: Wk 62 (>=17 y)- Std 3 min2.3
High B: Wk 62 (>=17 y)- Std 3 min2.9
Low B: Wk 78 (>=17 y)- Sup 3 min6.7
High B: Wk 78 (>=17 y)- Sup 3 min1.7
Low B: Wk 78 (>=17 y)- Std 1 min6.7
High B: Wk 78 (>=17 y)- Std 1 min6.7
Low B: Wk 78 (>=17 y)- Std 3 min6.7
High B: Wk 78 (>=17 y)- Std 3 min5.0
Low B: Wk 94 (>=17 y)- Sup 3 min6.1
High B: Wk 94 (>=17 y)- Sup 3 min0.7
Low B: Wk 94 (>=17 y)- Std 1 min2.7
High B: Wk 94 (>=17 y)- Std 1 min4.1
Low B: Wk 94 (>=17 y)- Std 3 min1.4
High B: Wk 94 (>=17 y)- Std 3 min2.7
Low B: Wk 118 (>=17 y)- Sup 3 min2.2
High B: Wk 118 (>=17 y)- Sup 3 min2.2
Low B: Wk 118 (>=17 y)- Std 1 min2.2
High B: Wk 118 (>=17 y)- Std 1 min3.3
Low B: Wk 118 (>=17 y)- Std 3 min2.2
High B: Wk 118 (>=17 y)- Std 3 min4.4
High A: Wk 142 (>=17 y)- Sup 3 min1.6
Low B: Wk 142 (>=17 y)- Sup 3 min6.3
High B: Wk 142 (>=17 y)- Sup 3 min4.8
High A: Wk 142 (>=17 y)- Std 1 min3.2
High B: Wk 142 (>=17 y)- Std 1 min7.9
High A: Wk 142 (>=17 y)- Std 3 min1.6
Low B: Wk 142 (>=17 y)- Std 3 min3.2
High B: Wk 142 (>=17 y)- Std 3 min7.9
Low B: Wk 166 (>=17 y)- Sup 3 min3.8
High B: Wk 166 (>=17 y)- Sup 3 min1.9
Low B: Wk 166 (>=17 y)- Std 1 min2.0
High B: Wk 166 (>=17 y)- Std 1 min5.9
High B: Wk 166 (>=17 y)- Std 3 min5.9
Low B: Wk 190 (>=17 y)- Sup 3 min2.9
High B: Wk 190 (>=17 y)- Sup 3 min8.8
High B: Wk 190 (>=17 y)- Std 1 min11.8
High B: Wk 190 (>=17 y)- Std 3 min17.6
High B: Wk 214 (>=17 y)- Sup 3 min5.9
High B: Wk 214 (>=17 y)- Std 1 min5.9
High B: Wk 214 (>=17 y)- Std 3 min5.9
Low B: Early TV (>=17 y)- Sup 3 min3.6
High B: Early TV (>=17 y)- Sup 3 min1.8
High: Early TV (>=12 y-<17 y)- Std 1 min33.3
Low B: Early TV (>=17 y)- Std 1 min3.6
High B: Early TV (>=17 y)- Std 1 min5.5
Low A: TV (>=17 years)- Sup 3 min2.0
Low B: TV (>=17 years)- Sup 3 min4.0
High B: TV (>=17 years)- Sup 3 min2.0
Low B: TV (>=17 years)- Std 1 min2.0
High B: TV (>=17 years)- Std 1 min4.0
Low B: TV (>=17 years)- Std 3 min2.0
High B: TV (>=17 years)- Std 3 min2.0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Systolic Blood Pressure)

TEMA values of Systolic Blood Pressure (BP) results were those that were observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<80 millimeters of mercury (mmHg)' (Low) and '\>140 mmHg' (High). For the age range, '\>=12 years - \<17 years', the abnormality criteria were '\<90 mmHg' (Low) and '\>160 mmHg' (High). For the age range, '\>=17 years', the abnormality criteria were '\<=90 mmHg and decrease from Baseline of \>=20 mmHg' (Low A), '\>=180 mmHg and increase from Baseline of \>=20' mmHg (High A), '\<90 mmHg' (Low B), '\>140 mmHg (High B), and '\>160 mmHg' (High C). Systolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Systolic Blood Pressure)
percentage of participantsAll Participants (Lacosamide)
High B: Wk 2 (>=17 y)- Sup 3 min3.5
Low B: Wk 2 (>=17 y)- Std 1 min1.0
High B: Wk 2 (>=17 y)- Std 1 min2.5
High B: Wk 2 (>=17 y)- Std 3 min3.6
High B: Wk 6 (>=17 y)- Sup 3 min3.1
High B: Wk 6 (>=17 y)- Std 1 min2.0
Low B: Wk 6 (>=17 y)- Std 3 min0.5
High B: Wk 6 (>=17 y)- Std 3 min3.6
Low B: Wk 14 (>=17 y)- Sup 3 min0.5
High B: Wk 14 (>=17 y)- Sup 3 min3.1
High B: Wk 14 (>=17 y)- Std 1 min3.6
High B: Wk 14 (>=17 y)- Std 3 min3.6
High B: Wk 22 (>=17 y)- Sup 3 min4.2
High B: Wk 22 (>=17 y)- Std 1 min4.2
High B: Wk 22 (>=17 y)- Std 3 min3.7
Low B: Wk 30 (>=17 y)- Sup 3 min0.8
High B: Wk 30 (>=17 y)- Sup 3 min5.9
High B: Wk 30 (>=17 y)- Std 1 min2.5
High B: Wk 30 (>=17 y)- Std 3 min5.0
Low B: Wk 38 (>=17 y)- Sup 3 min0.9
High B: Wk 38 (>=17 y)- Sup 3 min2.8
Low B: Wk 38 (>=17 y)- Std 1 min0.9
High B: Wk 38 (>=17 y)- Std 1 min2.8
High B: Wk 38 (>=17 y)- Std 3 min3.7
Low: Wk 46 (>=12 y-<17 y)- Sup 3 min6.3
High B: Wk 46 (>=17 y)- Sup 3 min2.9
Low: Wk 46 (>=12 y-<17 y)- Std 1 min6.3
High B: Wk 46 (>=17 y)- Std 1 min2.3
Low: Wk 46 (>=12 y-<17 y)- Std 3 min6.3
High B: Wk 46 (>=17 y)- Std 3 min3.4
High C: Wk 46 (>=17 y)- Std 3 min0.6
Low B: Wk 62 (>=17 y)- Sup 3 min0.6
High B: Wk 62 (>=17 y)- Sup 3 min3.5
Low: Wk 62 (>=12 y-<17 y)- Std 1 min6.3
Low A: Wk 62 (>=17 y)- Std 1 min0.6
Low B: Wk 62 (>=17 y)- Std 1 min0.6
High B: Wk 62 (>=17 y)- Std 1 min2.3
Low A: Wk 62 (>=17 y)- Std 3 min0.6
Low B: Wk 62 (>=17 y)- Std 3 min1.7
High B: Wk 62 (>=17 y)- Std 3 min1.2
Low A: Wk 78 (>=17 y)- Sup 3 min1.7
High B: Wk 78 (>=17 y)- Sup 3 min1.7
High B: Wk 78 (>=17 y)- Std 1 min1.7
High B: Wk 78 (>=17 y)- Std 3 min1.7
High B: Wk 94 (>=17 y)- Sup 3 min4.1
High B: Wk 94 (>=17 y)- Std 1 min4.1
High B: Wk 94 (>=17 y)- Std 3 min4.1
High B: Wk 118 (>=17 y)- Sup 3 min5.4
High C: Wk 118 (>=17 y)- Sup 3 min1.1
High B: Wk 118 (>=17 y)- Std 1 min5.5
High C: Wk 118 (>=17 y)- Std 1 min1.1
High B: Wk 118 (>=17 y)- Std 3 min6.6
High C: Wk 118 (>=17 y)- Std 3 min1.1
High B: Wk 142 (>=17 y)- Sup 3 min6.3
High B: Wk 142 (>=17 y)- Std 1 min6.3
High B: Wk 142 (>=17 y)- Std 3 min6.3
High B: Wk 166 (>=17 y)- Sup 3 min3.8
High B: Wk 166 (>=17 y)- Std 1 min7.8
High B: Wk 166 (>=17 y)- Std 3 min7.8
High B: Wk 190 (>=17 y)- Sup 3 min2.9
High B: Wk 214 (>=17 y)- Std 1 min5.9
High C: Wk 214 (>=17 y)- Std 1 min5.9
High B: Wk 214 (>=17 y)- Std 3 min5.9
High B: Wk 262 (>=17 y)- Std 3 min100
High B: Early TV (>=17 y)- Sup 3 min1.8
High B: Early TV (>=17 y)- Std 1 min1.8
High B: TV (>=17 y)- Std 1 min4.0
High B: TV (>=17 y)- Std 3 min2.0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Diastolic Blood Pressure)

TEMA values of Diastolic BP results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '3 years -\<12 years', the abnormality criteria were '\<50 mmHg' (Low) and '\>80 mmHg' (High), '\>=12 years - \<17 years', the abnormality criteria were '\<=50 mmHg' (Low) and '\>=105 mmHg' (High), and '\>=17 years', the abnormality criteria were '\<=50 mmHg and decrease from Baseline of \>=15 mmHg' (Low A), '\>=105 mmHg and increase from Baseline of \>=15' mmHg (High A), '\<50 mmHg' (Low B), '\>90 mmHg' (High B), and '\>100 mmHg' (High C). Diastolic BP were reported as per positions such as 'Sup 3 min', 'Std 1 min, and 'Std 3 min'.

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Diastolic Blood Pressure)
percentage of participantsAll Participants (Lacosamide)
Low: Wk 2 (3 y-<12 y)- Sup 3 min6.3
Low B: Wk 2 (>=17 y)- Sup 3 min0.5
High B: Wk 2 (>=17 y)- Sup 3 min2.5
Low: Wk 2 (3 y-<12 y)- Std 1 min6.3
High: Wk 2 (3 y-<12 y)- Std 1 min6.3
High B: Wk 2 (>=17 y)- Std 1 min5.1
High C: Wk 2 (>=17 y)- Std 1 min0.5
Low: Wk 2 (3 y-<12 y)- Std 3 min6.3
High: Wk 2 (3 y-<12 y)- Std 3 min12.5
High B: Wk 2 (>=17 y)- Std 3 min6.1
High C: Wk 2 (>=17 y)- Std 3 min0.5
Low A: Wk 6 (>=17 y)- Sup 3 min0.5
High B: Wk 6 (>=17 y)- Sup 3 min4.6
High C: Wk 6 (>=17 y)- Sup 3 min0.5
Low A: Wk 6 (>=17 y)- Std 1 min0.5
High A: Wk 6 (>=17 y)- Std 1 min0.5
High B: Wk 6 (>=17 y)- Std 1 min4.1
High C: Wk 6 (>=17 y)- Std 1 min0.5
High: Wk 6 (3 y-<12 y)- Std 3 min7.1
Low A: Wk 6 (>=17 y)- Std 3 min0.5
Low B: Wk 6 (>=17 y)- Std 3 min0.5
High B: Wk 6 (>=17 y)- Std 3 min6.6
High C: Wk 6 (>=17 y)- Std 3 min0.5
High: Wk 14 (3 y-<12 y)- Sup 3 min7.7
High B: Wk 14 (>=17 y)- Sup 3 min2.0
High C: Wk 14 (>=17 y)- Sup 3 min0.5
High A: Wk 14 (>=17 y)- Std 1 min0.5
High B: Wk 14 (>=17 y)- Std 1 min3.1
High C: Wk 14 (>=17 y)- Std 1 min1.0
High: Wk 14 (3 y-<12 y)- Std 3 min8.3
High B: Wk 14 (>=17 y)- Std 3 min4.6
High C: Wk 14 (>=17 y)- Std 3 min0.5
High: Wk 22 (3 y-<12 y)- Sup 3 min15.4
Low: Wk 22 (>=12 y-<17 y)- Sup 3 min6.3
High B: Wk 22 (>=17 y)- Sup 3 min1.6
High C: Wk 22 (>=17 y)- Sup 3 min0.5
High: Wk 22 (3 y-<12 y)- Std 1 min15.4
Low A: Wk 22 (>=17 y)- Std 1 min1.1
Low B: Wk 22 (>=17 y)- Std 1 min0.5
High B: Wk 22 (>=17 y)- Std 1 min7.9
High C: Wk 22 (>=17 y)- Std 1 min0.5
High: Wk 22 (3 y-<12 y)- Std 3 min7.7
Low A: Wk 22 (>=17 y)- Std 3 min0.5
High B: Wk 22 (>=17 y)- Std 3 min6.3
High C: Wk 22 (>=17 y)- Std 3 min1.1
High B: Wk 30 (>=17 y)- Sup 3 min3.4
High C: Wk 30 (>=17 y)- Sup 3 min0.8
High: Wk 30 (3 y-<12 y)- Std 1 min14.3
High A: Wk 30 (>=17 y)- Std 1 min0.8
High B: Wk 30 (>=17 y)- Std 1 min5.9
High C: Wk 30 (>=17 y)- Std 1 min0.8
High B: Wk 30 (>=17 y)- Std 3 min4.2
High B: Wk 38 (>=17 y)- Sup 3 min2.8
High: Wk 38 (3 y-<12 y)- Std 1 min20.0
High B: Wk 38 (>=17 y)- Std 1 min5.6
High C: Wk 38 (>=17 y)- Std 1 min0.9
High B: Wk 38 (>=17 y)- Std 3 min9.3
Low A: Wk 46 (>=17 y)- Sup 3 min0.6
High B: Wk 46 (>=17 y)- Sup 3 min4.0
Low: Wk 46 (>=12 y-<17 y)- Std 1 min6.3
High B: Wk 46 (>=17 y)- Std 1 min8.0
High C: Wk 46 (>=17 y)- Std 1 min0.6
High B: Wk 46 (>=17 y)- Std 3 min9.8
High C: Wk 46 (>=17 y)- Std 3 min1.1
High A: Wk 62 (>=17 y)- Sup 3 min0.6
High B: Wk 62 (>=17 y)- Sup 3 min5.2
High C: Wk 62 (>=17 y)- Sup 3 min1.2
High: Wk 62 (3 y-<12 y)- Std 1 min20.0
Low: Wk 62 (>=12 y-<17 y)- Std 1 min6.3
High A: Wk 62 (>=17 y)- Std 1 min0.6
High B: Wk 62 (>=17 y)- Std 1 min5.8
High C: Wk 62 (>=17 y)- Std 1 min1.2
Low B: Wk 62 (>=17 y)- Std 3 min0.6
High B: Wk 62 (>=17 y)- Std 3 min5.8
High C: Wk 62 (>=17 y)- Std 3 min0.6
Low: Wk 78 (>=12 y-<17 y)- Sup 3 min16.7
High B: Wk 78 (>=17 y)- Sup 3 min1.7
High B: Wk 78 (>=17 y)- Std 1 min3.3
High B: Wk 78 (>=17 y)- Std 3 min3.3
High C: Wk 78 (>=17 y)- Std 3 min1.7
High B: Wk 94 (>=17 y)- Sup 3 min1.4
High B: Wk 94 (>=17 y)- Std 1 min4.1
High: Wk 94 (3 y-<12 y)- Std 3 min14.3
High A: Wk 94 (>=17 y)- Std 3 min0.7
High B: Wk 94 (>=17 y)- Std 3 min4.7
High C: Wk 94 (>=17 y)- Std 3 min0.7
Low A: Wk 118 (>=17 y)- Sup 3 min1.1
High A: Wk 118 (>=17 y)- Sup 3 min1.1
Low B: Wk 118 (>=17 y)- Sup 3 min1.1
High B: Wk 118 (>=17 y)- Sup 3 min2.2
High C: Wk 118 (>=17 y)- Sup 3 min1.1
Low A: Wk 118 (>=17 y)- Std 1 min1.1
Low B: Wk 118 (>=17 y)- Std 1 min1.1
High B: Wk 118 (>=17 y)- Std 1 min4.4
High B: Wk 118 (>=17 y)- Std 3 min7.7
High B: Wk 142 (>=17 y)- Sup 3 min6.3
High B: Wk 142 (>=17 y)- Std 1 min7.9
High B: Wk 142 (>=17 y)- Std 3 min7.9
High B: Wk 166 (>=17 y)- Sup 3 min3.8
High B: Wk 166 (>=17 y)- Std 1 min5.9
High A: Wk 166 (>=17 y)- Std 3 min2.0
High B: Wk 166 (>=17 y)- Std 3 min11.8
High C: Wk 166 (>=17 y)- Std 3 min2.0
High B: Wk 190 (>=17 y)- Std 3 min2.9
High B: Wk 214 (>=17 y)- Sup 3 min5.9
High A: Wk 214 (>=17 y)- Std 1 min5.9
High B: Wk 214 (>=17 y)- Std 1 min5.9
High C: Wk 214 (>=17 y)- Std 1 min5.9
High A: Wk 214 (>=17 y)- Std 3 min5.9
High B: Wk 214 (>=17 y)- Std 3 min5.9
High C: Wk 214 (>=17 y)- Std 3 min5.9
High B: Early TV (>=17 y)- Sup 3 min3.6
High C: Early TV (>=17 y)- Sup 3 min1.8
High B: Early TV (>=17 y)- Std 1 min9.1
High C: Early TV (>=17 y)- Std 1 min1.8
High A: Early TV (>=17 y)- Std 3 min1.8
High B: Early TV (>=17 y)- Std 3 min10.9
High C: Early TV (>=17 y)- Std 3 min3.6
High: TV (3 y-<12 y)- Sup 3 min16.7
High B: TV (>=17 y)- Sup 3 min4.0
High B: TV (>=17 y)- Std 1 min2.0
High B: TV (>=17 y)- Std 3 min4.0
High C: TV (>=17 y)- Std 3 min2.0
SecondaryPercentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Body Weight)

TEMA values are defined in the SAP as significant deviations from the expected range of age-appropriate values. TEMA vital signs parameter results were those that are observed post- BL during the Treatment Period but not present at Baseline. For the age range, '1 month - \<17 years', the abnormality criteria were '\<3% of normal body weight' in Kilograms (kg) or '\>97% of normal body weight' in kgs. Here, '\<3% of normal' is presented as 'Low' and '\>97% of normal' is presented as 'High'. For the age range '\>=17 years', the abnormality criteria were 'Increase/decrease of \>=10%' body weight in kgs (presented as Inc/Dec A) or 'Increase/decrease of \>=7%' body weight in kgs (presented as Inc/Dec B).

Time frame:
During the study (up to approximately 5 years)
Reported as:
Number · percentage of participants
Percentage of Study Participants With Treatment-emergent Marked Abnormalities (TEMAs) in Vital Sign Measurements (Body Weight)
percentage of participantsAll Participants (Lacosamide)
High- Wk 14 (1 m - <17 y)9.7
Inc/Dec A- Wk 14 (>=17 y)5.6
Inc/Dec B- Wk 14 (>=17 y)16.4
High- Wk 30 (1 m - <17 y)10.5
Inc/Dec A- Wk 30 (>=17 y)5.9
Inc/Dec B- Wk 30 (>=17 y)19.3
High- Wk 46 (1 m - <17 y)7.1
Inc/Dec A- Wk 46 (>=17 y)12.4
Inc/Dec B- Wk 46 (>=17 y)22.6
High- Wk 62 (1 m - <17 y)7.7
Inc/Dec A- Wk 62 (>=17 y)14.9
Inc/Dec B- Wk 62 (>=17 y)21.8
Inc/Dec A- Wk 78 (>=17 y)19.0
Inc/Dec B- Wk 78 (>=17 y)30.2
High- Wk 94 (1 m - <17 y)13.0
Inc/Dec A- Wk 94 (>=17 y)16.4
Inc/Dec B- Wk 94 (>=17 y)30.9
Low- Wk 118 (1 m - <17 y)5.3
High- Wk 118 (1 m - <17 y)10.5
Inc/Dec A- Wk 118 (>=17 y)21.6
Inc/Dec B- Wk 118 (>=17 y)33.0
Low- Wk 142 (1 m - <17 y)7.7
High- Wk 142 (1 m - <17 y)7.7
Inc/Dec A- Wk 142 (>=17 y)19.5
Inc/Dec B- Wk 142 (>=17 y)32.5
High- Wk 166 (1 m - <17 y)10.0
Inc/Dec A- Wk 166 (>=17 y)25.0
Inc/Dec B- Wk 166 (>=17 y)45.0
Low- Wk 190 (1 m - <17 y)16.7
Inc/Dec A- Wk 190 (>=17 y)26.1
Inc/Dec B- Wk 190 (>=17 y)50.0
Low- Wk 214 (1 m - <17 y)50.0
Inc/Dec A- Wk 214 (>=17 y)31.8
Inc/Dec B- Wk 214 (>=17 y)54.5
Inc/Dec A- Wk 238 (>=17 y)16.7
Inc/Dec B- Wk 238 (>=17 y)50.0
Inc/Dec A- Wk 262 (>=17 y)33.3
Inc/Dec B- Wk 262 (>=17 y)33.3
Inc/Dec A- Early TV (>=17 y)26.3
Inc/Dec B- Early TV (>=17 y)33.3
High- TV (1 m - <17 y)21.4
Inc/Dec A- TV (>=17 y)34.5
Inc/Dec B- TV (>=17 y)52.7
SecondaryPercent Change in Primary Generalized Tonic-clonic Seizure (PGTCS) Frequency Per 28 Days From Combined Baseline

The 28-day PGTCS frequency during the relative period was subtracted from the 28-day Combined Baseline PGTCS frequency and the result was divided by 28-day Combined Baseline PGTCS frequency and the result was then multiplied by 100 to get percent change in PGTCS frequency per 28 days from Combined Baseline Period (CB) to the appropriate analysis Period. The CB was defined as the combined 12-week Historical Baseline and 4-week Prospective Baseline periods immediately prior to randomization in the study SP0982 or prior to Visit 1 (first dose) if direct enrollers in EP0012.

Time frame:
From Combined Baseline until end of Treatment Period (up to approximately 5 years)
Reported as:
Median · percent change
Percent Change in Primary Generalized Tonic-clonic Seizure (PGTCS) Frequency Per 28 Days From Combined Baseline
percent changeAll Participants (Lacosamide)
Percent Change in Primary Generalized Tonic-clonic Seizure (PGTCS) Frequency Per 28 Days From Combined Baseline-88.58 (-100.0 to 465.4)

Adverse events

Collected over From Visit 1 (Week 0) to End of Treatment Period (up to approximately 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants (Lacosamide)4/239 (1.7%)54/239 (22.6%)176/239 (73.6%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventAll Participants (Lacosamide)
Grand mal convulsionNervous system disorders16/239
Status epilepticusNervous system disorders4/239
VomitingGastrointestinal disorders2/239
Head injuryInjury, poisoning and procedural complications2/239
Facial bones fractureInjury, poisoning and procedural complications2/239
Subdural haematomaInjury, poisoning and procedural complications2/239
Myoclonic epilepsyNervous system disorders2/239
Suicide attemptPsychiatric disorders2/239
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders2/239
Cardiac failureCardiac disorders1/239
Most frequent other events
Showing 10 of 19
Most frequent other events
EventAll Participants (Lacosamide)
HeadacheNervous system disorders56/239
DizzinessNervous system disorders53/239
NasopharyngitisInfections and infestations52/239
SomnolenceNervous system disorders40/239
ContusionInjury, poisoning and procedural complications24/239
NauseaGastrointestinal disorders23/239
VertigoEar and labyrinth disorders19/239
DiarrhoeaGastrointestinal disorders18/239
InfluenzaInfections and infestations18/239
Upper respiratory tract infectionInfections and infestations17/239

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all study participants who received at least 1 dose of IMP during this study.

Age, Continuous
Age, Continuous(years)All Participants (Lacosamide)
Mean27.9 ± 12.6
Age, Customized
Age, Customized(Participants)All Participants (Lacosamide)
≥4-<12 years16
12-<18 years28
18-<65 years194
≥65 years1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants (Lacosamide)
Female134
Male105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants (Lacosamide)
American Indian/Alaskan Native1
Asian48
Black4
White178
Other/Mixed8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants (Lacosamide)
Hispanic or Latino28
Not Hispanic or Latino211
09

Study locations

87 sites
  • EP0012 5
    Little Rock, Arkansas 72205, United States
  • EP0012 8
    Santa Monica, California 90404, United States
  • Ep0012 31
    Colorado Springs, Colorado 80907, United States
  • Ep0012 42
    Loxahatchee Groves, Florida 33470, United States
  • Ep0012 13
    Panama City, Florida 32405, United States
  • EP0012 2
    Port Charlotte, Florida 33952, United States
  • Ep0012 15
    Boise, Idaho 83702, United States
  • Ep0012 21
    Peoria, Illinois 61637, United States
  • Ep0012 25
    Golden Valley, Minnesota 55422, United States
  • Ep0012 43
    New York, New York 10016, United States
  • Ep0012 53
    Austin, Texas 78758, United States
  • Ep0012 50
    Greenville, Texas 75401, United States
  • Ep0012 34
    Houston, Texas 77005, United States
  • Ep0012 38
    San Antonio, Texas 78229, United States
  • Ep0012 27
    Renton, Washington 98057, United States
  • Ep0012 23
    Madison, Wisconsin 53715, United States
  • Ep0012 980
    Chatswood, Australia
  • Ep0012 985
    Heidelberg, Australia
  • Ep0012 986
    Melbourne, Australia
  • Ep0012 981
    Parkville, Australia
  • Ep0012 181
    Curitiba, Brazil
  • Ep0012 180
    Florianopolis, Brazil
  • Ep0012 186
    Passo Fundo, Brazil
  • Ep0012 185
    Porto Alegre, Brazil
  • Ep0012 188
    Rio de Janeiro, Brazil
  • Ep0012 183
    Sao Paulo, Brazil
  • Ep0012 500
    Blagoevgrad, Bulgaria
  • Ep0012 501
    Sofia, Bulgaria
  • Ep0012 971
    Beijing, China
  • Ep0012 976
    Changchun, China
  • Ep0012 972
    Shanghai, China
  • Ep0012 550
    Ostrava- Poruba, Czechia
  • Ep0012 553
    Prague, Czechia
  • Ep0012 556
    Praha 11, Czechia
  • Ep0012 552
    Zlin, Czechia
  • Ep0012 255
    Bron Cedex, France
  • Ep0012 252
    Lille Cedex, France
  • Ep0012 251
    Nancy, France
  • Ep0012 303
    Erlangen, Germany
  • Ep0012 314
    Freiburg, Germany
  • Ep0012 311
    Marburg, Germany
  • Ep0012 600
    Budapest, Hungary
  • Ep0012 603
    Szeged, Hungary
  • Ep0012 850
    Rehovot, Israel
  • Ep0012 851
    Tel Hashomer, Israel
  • Ep0012 351
    Torino, Italy
  • Ep0012 906
    Fukuoka-shi, Japan
  • Ep0012 910
    Gifu, Japan
  • Ep0012 903
    Hamamatsu, Japan
  • Ep0012 902
    Hiroshima, Japan
  • Ep0012 912
    Kagoshima-city, Japan
  • Ep0012 914
    Kodaira-city, Japan
  • Ep0012 909
    Kokubunji-shi, Japan
  • Ep0012 901
    Niigata-city, Japan
  • Ep0012 911
    Omura-shi, Japan
  • Ep0012 900
    Sapporo-city, Japan
  • Ep0012 908
    Shinjuku-ku, Japan
  • Ep0012 940
    Daegu, Korea, Republic of
  • Ep0012 941
    Seoul, Korea, Republic of
  • Ep0012 944
    Seoul, Korea, Republic of
  • Ep0012 161
    Guadalajara, Mexico
  • Ep0012 657
    Czestochowa, Poland
  • Ep0012 655
    Gdansk, Poland
  • Ep0012 652
    Gliwice, Poland
  • Ep0012 651
    Katowice, Poland
  • Ep0012 653
    Katowice, Poland
  • Ep0012 654
    Katowice, Poland
  • Ep0012 656
    Tyniec Maly, Poland
  • Ep0012 650
    Warszawa, Poland
  • Ep0012 659
    Warszawa, Poland
  • Ep0012 451
    Lisboa, Portugal
  • Ep0012 704
    Iasi, Romania
  • Ep0012 700
    Timisoara, Romania
  • Ep0012 757
    Ekaterinburg, Russian Federation
  • Ep0012 750
    Kazan, Russian Federation
  • Ep0012 758
    Pyatigorsk, Russian Federation
  • Ep0012 756
    Saint Petersburg, Russian Federation
  • Ep0012 752
    Samara, Russian Federation
  • Ep0012 755
    St. Petersburg, Russian Federation
  • Ep0012 821
    Bardejov, Slovakia
  • Ep0012 823
    Hlohovec, Slovakia
  • Ep0012 402
    Barcelona, Spain
  • Ep0012 406
    Cordoba, Spain
  • Ep0012 407
    Madrid, Spain
  • Ep0012 403
    Sevilla, Spain
  • Ep0012 961
    Taichung, Taiwan
  • Ep0012 960
    Taipei, Taiwan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Mar 2023, 91 months.

Results were first posted in Dec 2023, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2015
First posted
Apr 3, 2015
StartActual
Aug 3, 2015
Primary completionActual
Mar 30, 2023
CompletionActual
Mar 30, 2023
Results first posted
Dec 14, 2023
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02408549
Responsible party
Sponsor
First posted
Apr 3, 2015
Start date
Aug 3, 2015
Primary completion
Mar 30, 2023
Completion
Mar 30, 2023
Results posted
Dec 14, 2023
Last update
Dec 14, 2023

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lacosamide

Start the discussion